[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventilator-associated-pneumonia-vap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventilator-associated-pneumonia-vap":192},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,71,99,122,153,179,207,227,255,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100602873","pulmonary-microbiota-changes-and-clinical-outcomes-in-neurosurgical-icu-patients-with-artificial-airways-100602873",false,"NCT07129174","Pulmonary Microbiota Changes and Clinical Outcomes in Neurosurgical ICU Patients With Artificial Airways","Association Between Changes in Pulmonary Microbiota and Clinical Outcomes in Neurosurgical ICU Patients With Artificial Airways: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Patients must meet all of the following conditions to be eligible for inclusion:\n\n  1. First admission to the Intensive Care Unit (ICU).\n  2. Assessed by an ICU specialist as expected to require artificial airway support (e.g., mechanical ventilation) for more than 24 hours.\n  3. Neurosurgical patients. Postoperative neurosurgical patients are defined in this study as those who have undergone surgery for: brain tumors, Subarachnoid hemorrhage, Traumatic brain injury\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria will be excluded:\n\n  1. Age under 18 years\n  2. Pregnancy\n  3. Pre-existing spinal cord injury\n  4. History of chronic pulmonary diseases, including: Chronic bronchitis, Chronic obstructive pulmonary disease (COPD), Bronchial asthma, Bronchiectasis, Interstitial lung disease, Pleural effusion\n  5. Pre-existing immunosuppressive conditions, including: Systemic immunomodulatory therapy, Chemotherapy, HIV infection, Other congenital or acquired immunodeficiency disorders\n  6. Receipt of systemic antimicrobial therapy within the past 3 months\n  7. Diagnosis of primary lung cancer or lung metastases from other tumors\n  8. History of partial lung resection for any reason","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","28 Days","OBSERVATIONAL","After neurosurgery, many patients need to stay in the intensive care unit (ICU) and use a breathing machine (mechanical ventilation) because of issues like decreased consciousness, weak breathing, or poor airway protection. During this period, the natural balance of bacteria in the lungs-known as the lung microbiota-can be disturbed by surgery, antibiotics, and airway procedures. This may reduce healthy bacteria and allow harmful bacteria to grow, increasing the risk of lung infections such as ventilator-associated pneumonia (VAP).\n\nThis study will follow 220 postoperative neurosurgical ICU patients at three centers: Beijing Tiantan Hospital, Beijing Shijitan Hospital, and Beijing Anzhen Hospital from August 2025 to August 2026. These patients will include those undergoing surgery for brain tumors, brain hemorrhage, or traumatic brain injury. Airway secretion samples (tracheal aspirates) will be collected shortly after surgery and at several subsequent time points to assess how lung bacteria change over time while patients are using a breathing machine.\n\nUsing advanced laboratory methods, the investigators will measure both the amount and types of bacteria in the lungs. The aim is to determine how these changes are related to patient outcomes, such as the occurrence of lung infections.\n\nThe results of this study may contribute to earlier detection of lung infections and the development of personalized treatment plans to improve recovery in ICU patients after neurosurgery.",[25,26,27],"Ventilator-Associated Pneumonia (VAP)","Intensive Care Unit (ICU) Patients","Microbiome Dysbiosis",[25,29,30],"Intensive care unit (ICU)","Pulmonary Microbiota","RECRUITING","2026-05-19",{"date":34,"type":35},"2026-05-22","ACTUAL",{"date":37,"type":35},"2025-08-30",{"date":39,"type":20},"2026-08-30",{"name":41,"class":42},"Jian-Xin Zhou","OTHER",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100580259","colistin-methanesulfonate-sodium-inhalation-for-prophylaxis-of-ventilator-associated-pneumonia-civap-a-prospective-multicentre-double-blind-randomized-placebo-controlled-trial-100580259","NCT06834971","Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","CIVAP","Participants will be enrolled if they meet the following criteria:\n\n1. Age ≥18 years;\n2. Mechanical ventilation for more than two consecutive days (48 hours);\n3. Patient has high-risk factors for multidrug-resistant bacterial infections, which meet any of the following criteria:\n\n(1)History of antibiotic exposure within 30 days; (2)Hospitalization time\\>5 days (120 hours); (3)Septic shock; (4) ARDS; (5)Accept renal replacement therapy; (6)Previous colonization of multidrug-resistant bacteria; 4. Informed consent of the patient or a proxy was written.\n\nParticipants will be excluded in case of:\n\n1. Suspected or confirmed VAP at the inclusion day;\n2. Patient ventilated through an endotracheal tube for more than four consecutive days (96 hours);\n3. Expected that endotracheal intubation will be removed within the next 24 hours;\n4. Tracheostomy;\n5. Allergy to CMS;\n6. Patients has polymyxins medication history within 7 days or clinical indication for systemic CMS therapy at the inclusion day;\n7. Chronic kidney failure with baseline glomerular filtration ≤30 mL\u002Fmin or Stage 3 classification AKI (KDIGO) (excluding patients undergoing renal replacement therapy);\n8. Expected survival time not exceeding 48 hours;\n9. Pregnancy or breastfeeding period;\n10. Patients previously included in this study or are using any inhaled antibiotics or are participating in other clinical studies within 30 days.",{"count":52,"type":20},508,"INTERVENTIONAL",[55],"NA","Previous studies have identified Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP) as the predominant pathogens responsible for ventilator-associated pneumonia (VAP). The challenge of drug resistance, especially against carbapenem is intensifying, with variations noted across different regions. Multidrug-resistant organisms associated VAP (MDR-VAP) are increasing in frequency and are associated with significant morbidity, mortality, therefore imposes a heavy burden on the healthcare system. Colistin methanesulfonate sodium (CMS) has shown effectiveness against gram-negative bacteria, including carbapenem-resistant organisms (CRO) such as carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Klebsiella pneumoniae (CRKP). This trial aims to evaluate the efficacy of a 3-day course of inhaled CMS in lowering the incidence of VAP among patients undergoing invasive mechanical ventilation for at least two days and at high risk of MDR-VAP.",[25],[59,60,61],"colistin","prevention","nebulization","2026-05-16",{"date":32,"type":35},{"date":65,"type":35},"2025-07-15",{"date":67,"type":20},"2026-12",{"name":69,"class":42},"Qilu Hospital of Shandong University",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":53,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100573226","immediate-versus-substantiated-antibiotic-therapy-in-suspected-non-severe-ventilator-associated-pneumonia-100573226","NCT06743529","Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia","Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia: A Randomized Controlled Trial","POSTPONE","Inclusion Criteria:\n\n* Invasive mechanical ventilation for longer than 48 hours\n* Respiratory sample collection taken less than two hours ago (at physician discretion, according to local protocol) for a first episode of suspected ventilator-associated pneumonia (meeting the following prespecified criteria) :\n\n  * new or changing chest X-ray infiltrates\n  * plus at least two of the following:\n\n    * body temperature ≥38.3°C or ≤35.5°C,\n    * blood leukocyte count \\>12 000\u002FµL or \\\u003C4000\u002FµL,\n    * purulent tracheobronchial aspirate.\n* Age ≥18 years\n* Informed consent from the patient or next of kin to participation in the trial, or emergency procedure if no next of kin is available\n* Patients affiliated to a social security system\n\nNon-inclusion Criteria:\n\n* Criteria for severe ventilator-associated pneumonia defined as:\n\n  * Vasopressor therapy for onset of septic shock around the time of ventilator-associated pneumonia suspicion\n  * Onset or severe worsening of hypoxemia (PaO2\u002FFiO2\\\u003C150 with 60% FiO2 and 10 mm H2O peak expiratory pressure, or patient on veno-venous extracorporeal membrane oxygenation)\n* Immunosuppression defined as :\n\n  * leukocytes \\\u003C1G\u002FL or neutrophils \\\u003C0,5 G\u002FL\n  * within the last 3 months\n  * hematopoietic stem-cell transplant or organ transplant with chronic immunosuppressant therapy\n  * HIV infection with CD4\\\u003C50\u002Fmm3\n  * chronic corticosteroid use (\\>0.5 mg\u002Fkg day for at least one month within the last three months).\n* Patient already on Antibiotic Therapy of predicted duration ≥4 weeks (endocarditis, spondylodiscitis, abscess...)\n* Previous ventilator-associated pneumonia suspicion with sampling and\u002For Antibiotic Therapy for suspected ventilator-associated pneumonia\n* Previous inclusion in the trial\n* Patient included in an interventional study on ventilator-associated pneumonia management with the same primary endpoint.\n* Pregnancy, recent delivery, or breastfeeding\n* Correctional facility inmate, adult under guardianship\n* Patient under legal protection\n* Life expectancy less than 48 h and\u002For decision not to treat potential pneumonia acquired under mechanical ventilation in the context of limiting\u002Fdiscontinuing treatment.\n* Organ donor reanimation",{"count":80,"type":20},686,[55],"Ventilator-associated pneumonia is the leading nosocomial infection in the intensive care units, and is associated with prolonged mechanical ventilation and overuse of antibiotics. Initiating antibiotic therapy immediately after bacteriological sampling (immediate strategy) may expose uninfected patients to unnecessary treatment, while waiting for bacteriological confirmation (conservative strategy) may delay ventilator-associated pneumonia in infected patients.\n\nThe decision to start antibiotic therapy for ventilator-associated pneumonia takes three points into account: diagnostic probability, the risks to the patient if Antibiotic Therapy is delayed, and the risk of selection of resistant bacteria. Diagnostic probability is limited, given the subjective and non-specific nature of the diagnostic criteria, and only 30-50% of suspected cases are confirmed bacteriologically (whereas samples are only taken when the pre-test probability is sufficient). The risks associated with delayed antibiotic therapy are unknown, as few observational studies have directly assessed the impact of the timing of Antibiotic Therapy initiation on outcome (frequent confusion between delayed and inappropriate Antibiotic Therapy).\n\nIregui et al. found that delaying Antibiotic Therapy by more than 24 hours was associated with higher mortality. However, more recent before-and-after studies have shown that the conservative strategy was associated with lower mortality, more frequently appropriate initial Antibiotic Therapy and shorter duration of Antibiotic Therapy. Similarly, in a recent before-and-after study by our team, initiating antibiotic therapy only upon microbiological confirmation of ventilator-associated pneumonia without septic shock or severe acute respiratory distress syndrome was not associated with an increase in ventilation time, length of stay or excess mortality at D28; but was associated with antibiotic therapy that was more often appropriate (DELAVAP, MARTIN et al, Annals of Intensive Care, 2024). Finally, the recent multicenter TARPP pilot study in surgical intensive care suggests that antibiotic therapy initiated on the basis of microbiological data in patients with suspected ventilator-associated pneumonia not requiring vasopressor support is not associated with a poorer outcome than immediate antibiotic therapy without documentation (the only randomized study on this subject).\n\nAntibiotic Therapy for suspected ventilator-associated pneumonia that is not subsequently confirmed is an unnecessary use of antibiotics and carries a risk of selection of resistant bacteria, with adverse effects on public health. It has been reported that a conservative Antibiotic Therapy prescription strategy for intensive care units -acquired infections reduces Antibiotic Therapy use and the incidence of acquired β-lactamase-producing Enterobacteriaceae infections.\n\nOverall, in patients with suspected ventilator-associated pneumonia but no signs of clinical severity, given the uncertainty about attributable mortality and concerns about bacterial resistance, the evaluation of the conservative Antibiotic Therapy strategy is reasonable. Some French intensive care units already delay Antibiotic Therapy until confirmation of ventilator-associated pneumonia, except in patients with severe hypoxemia or the need for vasopressor support.",[25],[85,86,87,88],"Intensive care medicine","Intensive care","Ventilator-associated pneumonia","antibiotic sparing","2026-03-23",{"date":91,"type":35},"2026-03-27",{"date":93,"type":35},"2025-11-11",{"date":95,"type":20},"2029-02-11",{"name":97,"class":42},"Nantes University Hospital",41,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100613589","real-world-effectiveness-of-aztreonam-avibactam-against-mbl-producing-cre-100613589","NCT07268560","Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","Aztreonam-Avibactam Real World Study Against Metallo-β-lactamase-Producing Carbapenem-Resistant Enterobacterales","AWARE","Inclusion Criteria:\n\n* 1\\. Age 18 years or older 2. Hospitalized with a diagnosis of confirmed cIAI or HAP\u002FVAP 3. Confirmed infection with MBL-producing CRE 4. Received on label use of ATM-AVI treatment for ≥24 hours 5. Informed consent will be obtained or waived.\n\nExclusion Criteria:\n\n* 1\\. Confirmed or suspected infection caused by Gram-negative species not expected to respond to ATM-AVI 2. Currently enrolled in an interventional clinical tria",{"count":108,"type":20},100,"Why This Study is Needed Some bacterial infections have become resistant to common antibiotics, making them very difficult to treat. This is a growing and serious health problem. A new combination drug, Aztreonam-Avibactam (we'll call it ATM-AVI), has been developed to fight these tough bacteria.\n\nThis new drug was recently approved for use in Europe (April 2024), the United States (February 2025), and China (June 2025). Because it is so new, there is very little information available, especially in China, on how well it works for real patients outside of initial testing.\n\nThis lack of real-world experience means we don't know enough about:\n\n* How effective it is for typical patients in China.\n* The types of patients and infections it is used for.\n* How it affects a patient's time in the hospital. This study aims to fill these gaps by looking at how ATM-AVI performs in Chinese hospitals, which will help doctors better treat these dangerous infections and improve patient recovery.\n\nWhat the Study Aims to Find Out\n\nMain Goal:\n\nTo see how well ATM-AVI works for adult patients in China with these specific antibiotic-resistant infections.\n\nOther Goals:\n\nTo gather more details about:\n\n* How patients are responding to the treatment at different points (e.g., after 5 days, at the end of treatment, and at a follow-up check).\n* Whether the bacteria causing the infection are cleared.\n* How the treatment affects the patient's hospital stay and use of resources.\n* The number of patients who, unfortunately, pass away during or after treatment.\n* The characteristics of the patients (like age) and their infections.\n* How doctors are using this new drug and if it's used alongside other antibiotics.\n\nHow the Study Will Work This is an observational study that will be conducted in about 30 hospitals across China. We plan to include around 100 adult patients who were hospitalized with these tough infections and received the new drug, ATM-AVI, for at least one full day.\n\nThe study will run from October 2025 to June 2027. We will look at both past (retrospective) and future (prospective) patients. For past patients, we will review their existing medical records. For future patients, we will ask for their permission (informed consent) before collecting any information.\n\nWe will collect information from patient records, such as:\n\n* Basic patient details and the nature of their infection.\n* How and when the ATM-AVI drug was used.\n* Details about their hospital stay.\n* The results of their lab tests. A doctor will assess and record how each patient is doing at key points: 5 days after starting the drug, at the end of the treatment, and at a follow-up check to see if the infection is cured.",[111,112,25],"Complicated Intra-Abdominal Infections, cIAIs","Hospital-acquired Pneumonia (HAP)","2026-03-19",{"date":89,"type":35},{"date":116,"type":35},"2025-12-25",{"date":118,"type":20},"2027-07-31",{"name":120,"class":42},"Sir Run Run Shaw Hospital",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":53,"phases":130,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":70},"100623494","impact-of-nurses-behavior-change-and-evidence-based-practice-implementation-on-quality-indicators-in-intensive-care-units-in-low--and-middle-income-countries-100623494","NCT07397364","Impact of Nurses' Behavior Change and Evidence-Based Practice Implementation on Quality Indicators in Intensive Care Units in Low- and Middle-Income Countries","Inclusion Criteria:\n\nFor nurses:\n\n* Willing to participate in this research.\n* hold the existing position for at least three months.\n* participants were required to have at least two years of critical care experience.\n\nFor patients:\n\n\\- No specific inclusion criteria\n\nExclusion Criteria:\n\n* for nurse:\n* Nurses intending to leave their jobs within the study period (five months) were excluded.\n\nFor patients:\n\n* admitted with Pressure ulcers.\n* intubated outside the NCI\n* Patients develop VAP in less than 48 hrs. after initiation of mechanical ventilation.",{"count":129,"type":20},50,[55],"Study title:\n\nImpact of nurses' behavior change and implementing evidence-based practice to improve quality indicators in intensive care units in low-and middle-income countries\n\nBackground and Rationale:\n\nQuality care is crucial for preventing adverse events and improving patient survival rates in healthcare settings, especially in the intensive care units (ICU). To improve patient outcomes, complying with evidence-based practice (EBP) and continuous monitoring of quality indicators by Plan-Do-Check- Act (PDCA) cycle is effective; in which \"P: decide and plan target actions\", \"D: implement the plans\", \"C: measure and evaluate the indicators\", and \"A: discuss the next step for improvement\". Regarding quality indicators at ICU, Japan has achieved the highest global survival rate with the fewest adverse events.\n\nIn a scoping review, when EBPs were implemented, 90% of the studies showed improved patient outcomes, and 94% found a positive return on investment. In ICU, EBP is essential for providing high-quality care, reducing errors, educating healthcare professionals, ensuring the efficacy of treatments, and fostering trust and good patient care relationships.\n\nIn Egypt, as a one of the low-and middle-income countries (LMICs), 59.9% of ICU patients had poor outcomes, with a 14.9% mortality rate. The incidence rate of total device- associated infections was 35.3\u002F1000 device-days. The incidence of VAP is 38.4%, and it has reached 75% in some Egyptian hospitals; contrarily, in Japan, where Bundle care (evidence-based guideline) is strictly followed by nurses, the incidence of VAP is only 5.7%. EBP is hindered in LMICs by a lack of research infrastructure, a knowledge gap, poor nursing management, and limitation of resources. However, promoting this change will require increased advocacy of nurses, technical advancements, and integration into curricula and continuing education programs. Moreover, global collaboration is imperative for comprehensive development.\n\nObjectives:\n\nPrimary Objective: Improve the quality of care in the ICU through implementation of EBP (indicated by selected quality indicators which assessed as routine work monthly in the selected ICU).\n\nSecondary Objective: To enhance ICU nurses' professional competency in applying EBP.\n\nThe level of compatibility between the research proposal and the department's research goals.\n\nThere is a high level of compatibility between the research proposal and the department's research goals, particularly in terms of enhancing the competency of ICU staff through targeted training, improving the quality of care, and ultimately contributing to better patient outcomes.\n\nThe level of compatibility between the research proposal and the NCI 's research Plan.\n\nThe research proposal demonstrates a high level of compatibility with the NCI's research plan through the implementation of the latest evidence-based practices (EBP), standardized care protocols, and up-to-date clinical guidelines. It also aims to reduce contributing factors associated with increased morbidity and complication rates, thereby aligning with the institute's goals to advance patient safety and care quality.\n\n\\- Study Design: An open- label, prospective, parallel-group (1:1), non-randomized controlled trial, with a pre- and post-design.",[25,133,134,135,136],"Central Line-Associated Bloodstream Infection","Pressure Ulcers (Hospital-acquired Pressure Injuries)","Prolonged Intensive Care Unit Length of Stay","ICU Mortality (Survival Rate)",[138,139,140,141,142],"Evidence-Based Practice","Nurses' Behavior Change","Intensive Care Unit","Quality Indicators","Ventilator-Associated Pneumonia","NOT_YET_RECRUITING","2026-02-04",{"date":146,"type":35},"2026-02-09",{"date":148,"type":20},"2026-03-01",{"date":150,"type":20},"2026-08-01",{"name":152,"class":42},"Cairo University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":53,"phases":163,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100621826","dynamic-airway-resistance--ml-guide-sputum-suction-in-ventilated-patients-100621826","NCT07375667","Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients","Mechanisms of Dynamic Airway Resistance Monitoring and Machine Learning for Assessing Pulmonary Inflammation and Guiding Sputum Suction in Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Clinical diagnosis of Acute Respiratory Distress Syndrome (ARDS)\n* Clinical diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)\n* Clinical diagnosis of Severe pneumonia\n\nExclusion Criteria:\n\n* Clinical diagnosis of multiple organ failure;\n* Clinical diagnosis of multiple organ bleeding;","90 Years",{"count":162,"type":20},258,[55],"Research has shown that timely suctioning not only improves survival rates but also enhances the quality of life in ventilator-dependent patients. However, clinical judgment on the optimal timing for suctioning currently relies primarily on physician experience, lacking scientific evidence \\[10\\]. Airway viscous resistance reflects the frictional resistance encountered by gas flow within the airways and is closely associated with airway patency. When airway secretions increase, viscous resistance undergoes dynamic changes. Therefore, analyzing these dynamic variations in viscous resistance derived from ventilator waveforms to determine the optimal suctioning timing and assess its clinical impact on the progression of pulmonary inflammation holds significant scientific value and offers new insights and methodologies for clinical practice.",[166,25,167],"Mechanical Ventilation Pressure High","Respiratory Depression Neonatal",[169],"Airway resistance","2026-01-26",{"date":172,"type":35},"2026-01-29",{"date":174,"type":35},"2025-10-30",{"date":176,"type":20},"2029-12-30",{"name":178,"class":42},"Affiliated Hospital of Nantong University",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":186,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":53,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":121},"100564082","effect-of-implementing-evidence-based-practice-and-nurses-behavior-change-on-quality-of-care-in-intensive-care-unit-focus-on-ventilator-associated-pneumonia-in-a-tertiary-hospital-in-bangladesh-100564082","NCT06624540","Effect of Implementing Evidence-based Practice and Nurse's Behavior Change on Quality of Care in Intensive Care Unit: Focus on Ventilator Associated Pneumonia in a Tertiary Hospital in Bangladesh","EBP in Nursing","Study 2:\n\nInclusion criteria:\n\n* Who will be a registered nurse in Bangladesh.\n* Who will agree to participate in this study and the EBP training.\n\nExclusion criteria:\n\n* Who will not directly involve patient care in ICU.\n\nStudy 3:\n\nInclusion Criteria:\n\n* Irrespective of age and sex, participant must be 18 years old.\n* Legal guardian of a patient consents to participation in the study\n* Intubated patients after admission.\n\nExclusion Criteria:\n\n* Who stays less than 2 days at the GICU.\n* Who dies or is extubated within 2 days after admitted in the GICU.\n* ICU readmission.",true,{"count":188,"type":20},272,[55],"Quality of care is crucial for preventing adverse events such as infection in the intensive care units (ICUs). The most common ICU-acquired infections include pneumonia such as ventilator-associated pneumonia (VAP), Central Line Bloodstream Infection (CLABSI), catheter-associated urinary tract in, Medical Device Related Pressure Ulcer (MDRPU) and Pressure Ulcer (PU). This study explores the patient outcome in ICU by examining the causes and prevalence of ICU-acquired infection. The implementation of evidence-based practice (EBP) to reduce infection and change the nurses practice (behavioral changes) to adhere with EBP based on simulation-based training.\n\nGeneral objective:\n\nTo evaluate the effect of EBP by using recent technologies-based equipment to prevent VAP and promote behavior change among nurses for better outcome of the patient in ICU.\n\nSpecific Objectives:\n\n1. To determine the incidence of adverse events (VAP rate, MDRPU rate, PU rate, CLABSI rate), length of stay and survival rate in ICU.\n2. To evaluate the effectiveness of EBP education by changing nurses' behavior and determine its impact on improving patient outcomes in the ICU.\n3. To evaluate the effectiveness of EBP including proper equipment use and changed nurses behavior acquired through the training for better patient outcome (VAP ratio) in the ICU.\n4. To examine the feasibility of evaluation process and outcomes and successful implementation of EBP in ICU.\n\nHypothesis:\n\nIt is hypothesize that implementing EBP in ICU, including new equipment use and nurses training, will improve patient outcome.\n\nThese research consist of three studies:\n\nPhase 1: Incidence of adverse events (VAP rate, MDRPU rate, PU rate, CLABSI rate), length of stay and survival rate in ICU. The patients of General ICU will be followed up after admission up to discharge or death at ICU. The investigators use the study findings for our subsequent intervention study 3 as historical data.\n\nPhase 2: A pre- and post- quasi-experimental study will be conducted for 6 months to evaluate the nurse's competency on EBP after getting 1-month EBP training. This study has 3 steps: (1) Pre-observation period to measure nurse's competency level for 2-month, (2) nurse's EBP training period with preparation for 1 month, and (3) post-implementation period to measure nurse's competency and implementation of EBP practice for 2 months. Study nurses will receive EBP training, EBP and proper equipment for patient management. The nurses will receive EBP education and training with necessary equipment, such as a close suction catheter, an endotracheal tube, a suction device, and a mouth care brush. In this study, use global standard equipment for the patients safety.\n\nPhase 3: A pre- and post- quasi-experimental study will be implemented to evaluate the efficacy of EBP implementation. The investigators use new equipment and implement EBP for patients and assess the patient outcomes. The investigators compare the findings from study 1 (as historical data) with the data from this study 3.\n\nThe investigators will compare the VAP infection prevalence and patients' outcomes related to ICU-acquired infection between pre- and post- test phase.",[192,193],"Ventilator Associated Pneumonia (VAP)","Evidence Based Practice",[195,196,197],"evidence based practice","Ventilator Associated Pneumonia","Nurses Knowledge","2025-12-09",{"date":200,"type":35},"2025-12-15",{"date":202,"type":35},"2024-10-10",{"date":204,"type":20},"2026-02-28",{"name":206,"class":42},"Hiroshima University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":225,"locationsCount":70},"100592453","heparin-binding-protein-versus-platelet-count-and-mean-platelet-volume-kinetics-in-the-diagnosis-and-prognosis-of-vap-100592453","NCT06993623","Heparin Binding Protein Versus Platelet Count and Mean Platelet Volume Kinetics in the Diagnosis and Prognosis of VAP","Heparin Binding Protein Versus Platelet Count and Mean Platelet Volume Kinetics as Indicators for Diagnosis and Prognosis of Ventilator Associated Pneumonia","Inclusion Criteria:\n\n* 1\\. Patients \\\u003C 18 years old\\\u003C70years 2. MV for more than 48 h. 3 . Signs of VAP according to clinical and radiological data , Modified Clinical Pulmonary Infection Score (CPIS) will be calculated for the patients and will be included when CPIS \\> 6 . Modified CPIS will be calculated without considering culture results.(12)\n\nExclusion Criteria:\n\n\\- . Patients with pre-existing infections or sepsis at ICU admission. 2. Patients with underlying conditions such cancer, chronic liver illnesses, end-stage renal disease, etc. that may impact platelet function or morphology.\n\n3\\. primary hematological disorders, disseminated intravascular coagulation. 4.severe thrombocytopenia (platelet count ≤ 20x109 L-1) and receiving platelet transfusion.","70 Years",{"count":216,"type":20},80,"mechanically ventilated for 48 hours or more and subsequently develop ventilator-associated pneumonia (VAP). After obtaining approval from the local ethical committee at the Faculty of Medicine, El-Minia University, and informed consent from first-degree relatives, patients will be enrolled and classified into two groups based on clinical outcomes: Group A (survivors with successful extubation) and Group B (non-survivors with prolonged mechanical ventilation and\u002For 30-day mortality). Prolonged mechanical ventilation (PMV) is defined as ≥21 days of ventilation. Blood samples will be collected from participants to measure heparin-binding protein (HBP), mean platelet volume (MPV), and the MPV-to-platelet count (PC) ratio. Laboratory analysis will be blinded to the clinical outcome group to ensure objectivity. The study aims to investigate the potential of these biomarkers in predicting prognosis and guiding clinical decisions in patients with VAP.",[192],"2025-09-22",{"date":221,"type":35},"2025-09-23",{"date":223,"type":20},"2025-09",{"date":67,"type":20},{"name":226,"class":42},"Esraa Hamdy Thabit Riad",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":53,"phases":236,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":121},"100578190","phase-4-a-study-to-evaluate-role-of-inhaled-amikacin-to-prevent-ventilator-associated-pneumonia-in-patients-with-cirrhosis-100578190","NCT06808074","A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis","Inhaled Amikacin as a Prophylaxis for Ventilator Associated Pneumonia in Patients With Cirrhosis: A Randomized Placebo Controlled Double Blind Study","Inclusion Criteria:\n\n1. Patients admitted to the liver ICU with hepatic encephalopathy (Grade 2 or higher), requiring intubation for at least 48 hours, without pneumonia.\n2. Patient is aged ≥18 years.\n3. Written informed consent of the patient or a proxy.\n\nExclusion Criteria:\n\n1. Suspected or confirmed Pneumonia at the day of inclusion.\n2. Patients with Chronic kidney disease on maintenance hemodialysis\n3. Stage 2 or 3 Kidney Disease Improving Global Outcome (KDIGO) classification AKI the day of inclusion. Patients undergoing renal replacement therapy or for whom decision has been made to initiate renal replacement therapy can be included whatever the KDIGO stage\n4. Pregnancy or breast-feeding.\n5. Clinical indication for systemic aminoglycoside therapy the day of inclusion: as deemed necessary by the clinician in charge.\n6. Patients known to be allergic to aminoglycosides.\n7. Patients who received intravenous Amikacin before 7 days of inclusion in this study.",{"count":235,"type":20},162,[237],"PHASE4","The recent AMIKINHAL trial found that prophylactic inhaled amikacin was effective in lowering the incidence of ventilator-associated pneumonia in ICU patients. Since aspiration is a common complication of cirrhosis patients with HE (7 out of 10 patients develop some type of HE) who are hospitalized to the liver ICU also have an elevated risk of Ventilator associated pneumonia. Despite supportive care and appropriate antimicrobial therapy pneumonia is linked to greater mortality in cirrhosis. This poses a significant challenge to physicians. Due to the lack of randomized controlled trials (RCTs) on the prophylaxis of VAP in cirrhosis patients with HE, conducting this study is necessary to evaluate the efficacy of inhaled amikacin. The study results may provide evidence -based guidance for therapy in this patient population.",[240,241,192],"Hepatic Encephalopathy","Cirrhosis",[243,244,245],"Inhaled amikacin","Prophylaxis","Ventilator associated pneumonia","2025-04-03",{"date":248,"type":35},"2025-04-04",{"date":250,"type":35},"2025-02-12",{"date":252,"type":20},"2026-05",{"name":254,"class":42},"Asian Institute of Gastroenterology, India",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":53,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100579066","inhaled-polymyxin-e-to-prevent-vap-100579066","NCT06819462","Inhaled Polymyxin E to Prevent VAP","Inhalaed Polymyxin E to Prevent Ventilator-associated Pneumonia: a Multicenter Clinical Study","Inclusion Criteria:\n\n1. Age \\>18 years old\n2. Patients with brain injury admitted to ICU (including brain injury caused by trauma, cerebral hemorrhage, cerebral infarction, and cardiac arrest)\n3. GCS score\\\u003C12 points\n4. Mechanical ventilation time ≥ 48 hours\n5. Sign informed consent\n\nExclusion Criteria:\n\n1. Existing lung diseases that require long-term inhaled medication treatment.\n2. Lower respiratory tract infection at admission.\n3. New or persistent infiltration on chest imaging within 48 hours after admission.\n4. Expected removal of endotracheal tube within the next 24 hours.\n5. Mechanical ventilation time before enrollment exceeds 96 hours.\n6. Tracheostomy patients.\n7. Current or recent use of polymyxin E (within 24 hours).\n8. Allergy to polymyxin E.\n9. Allergic pregnant or lactating women.\n10. Severe neuromuscular lesions.\n11. Severe other organ dysfunction. Expected short-term death (48 hours) or palliative treatment.\n12. Late stage solid organ or blood system tumors. Expected survival\\\u003C30 days. 13. Participate in other clinical studies within 30 days","80 Years",{"count":264,"type":20},434,[55],"Ventilator associated pneumonia is the most common manifestation of hospital acquired infections in ICU. The incidence of ventilator-associated pneumonia in patients receiving mechanical ventilation is as high as 20% -71%, which can lead to increased systemic antibiotic use, prolonged mechanical ventilation time and ICU stay, and increased treatment costs. In addition, ventilator-associated pneumonia is also the main cause of hospital infection related deaths in critically ill patients.\n\nHowever, there is a certain buffer time for patients to develop ventilator-associated pneumonia after receiving endotracheal intubation. Previous studies have found that the peak incidence occurs after 7 days of mechanical ventilation, so there is an opportunity for early treatment to prevent infection. Despite the implementation of numerous preventive measures for ventilator-associated pneumonia over the decades, such as reducing sedation and withdrawal protocols, patient positioning, oral care, prophylactic probiotics, prophylactic antibiotics, and the use of silver plated endotracheal tubes. Among them, the research on the preventive use of antibiotics has a history of over 30 years and is a topic of substantial debate. Prophylactic use of antibiotics includes systemic application and local nebulization inhalation, and inhaled antibiotics may be an effective measure for preventing ventilator-associated pneumonia. Potential extensively drug-resistant Gram negative (XDR-GN) bacteria, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, are common pathogens causing VAP in ICU. The mortality rate of VAP caused by XDR-GN pathogen may be higher than 70%. With the increasing incidence of multidrug-resistant microorganisms, nebulized or inhaled aminoglycoside antibiotics are often used as empirical or definitive treatment for VAP in ICU patients. The previous group of antibiotics, polymyxin, has returned to the view of medical staff. Sodium polymyxin E methanesulfonate has been used as a salvage therapy for XDR-GN bacteria causing pneumonia, demonstrating its activity against XDR-GN causing VAP in critically ill patients. The guidelines of the Infectious Diseases Society of America (IDSA) on hospital acquired pneumonia also indicate that patients with Gram negative pneumonia caused by drug-resistant bacteria are sensitive to polymyxins. In this randomized controlled study, we aim to investigate the effect of prophylactic use of polymyxin E nebulized inhalation on the incidence of VAP.",[25,268],"Inha'le'd","2025-02-05",{"date":271,"type":35},"2025-02-11",{"date":273,"type":20},"2025-02-01",{"date":275,"type":20},"2028-06-30",{"name":277,"class":42},"Southeast University, China",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":287,"conditions":288,"keywords":300,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":70},"100566342","study-of-sleep-quality-in-the-intensive-care-unit-and-association-with-weaning-from-invasive-ventilation-in-patients-with-chronic-obstructive-bronchopneumopathy-100566342","NCT06653933","Study of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy.","SLEECOP","Inclusion Criteria:\n\n* Patients diagnosed with COPD according to the GOLD criteria.\n* Mechanical ventilation by endotracheal tube and mechanical ventilation for \\> 24 hours.\n* Withdrawal of treatment with continuous sedation and\u002For neuroleptics.\n* Adequate recovery with Glasgow Coma Scale ≥ 8.\n\nExclusion Criteria:\n\n* Patients with central nervous system damage or neuromuscular pathology.\n* Pregnant or postpartum patients.\n* Patients or their relatives who object to participating in the study.",{"count":286,"type":20},42,"Patients admitted in ICU may require invasive mechanical ventilation, using a mechanical ventilator and an endotracheal tube.\n\nIn ICU, a prolonged duration of invasive mechanical ventilation may be responsible for ventilator-induced lung injury, pulmonary infection, prolonged administration of sedation, neuromyopathy and prolonged length of stay. The goal of the ICU healthcare teams is therefore to reduce the duration of invasive mechanical ventilation as much as possible.\n\nICU patients have many sleep disturbances: sleep fragmentation, sleep stage changes, changes in sleep architecture. These sleep disturbances are due to sedation and analgesia, delirium, patient care activities, noise and altered day-night cycles.\n\nChronic obstructive pulmonary disease (COPD) is a common respiratory disease. COPD complicates the management of invasive mechanical ventilation, particularly weaning of this invasive mechanical ventilation and extubation (removal of the intubation tube).\n\nTo reduce the risk of reintubation, it is recommended that a weaning test is performed prior to extubation. The purpose of this test is to simulate the conditions of breathing without the help of a ventilator after extubation. If the weaning test is successful, the patient can theoretically be extubated.\n\nThere are several causes associated with extubation failure, but studies suggest that sleep deprivation or poor sleep quality in the nights before extubation is one of them. In addition, patients with COPD often have chronic sleep disturbances or induced by their stay in the ICU (asthenia, bed rest, anxiety, sedation, etc.).\n\nThe aim of our study will be to compare the sleep characteristics of COPD patients with a failed weaning test and those with a successful test. Our hypothesis is that patients with a failed weaning test will have more sleep disturbances in the period of 72 hours before the weaning test.",[289,290,291,25,292,293,294,295,296,297,298,299],"COPD","COPD Exacerbation","Ventilated Patients","Ventilator Weaning","Weaning of Mechanical Ventilation","Sleep Quality","Sleep Disorders, Circadian Rhythm","Sleep Disorders","Failure, Respiratory","ICU Hospitalization","ICU Sedation",[289,294,293],"2024-10-21",{"date":303,"type":35},"2024-10-23",{"date":305,"type":20},"2025-01-01",{"date":307,"type":20},"2027-07-01",{"name":309,"class":42},"University Hospital, Grenoble"]